FDA CCIT Expectations

The FDA expects pharmaceutical manufacturers to demonstrate that sterile products maintain container closure integrity throughout manufacturing, storage, and distribution. Although the agency does not mandate a specific technology, it requires that methods be scientifically justified and control strategy be appropriate for the product-container system.

FDA inspectors commonly evaluate whether a company can demonstrate detection capability for clinically relevant defects. This includes reviewing validation documentation, method suitability studies, defect challenge results, and justification for acceptance criteria. Testing must be risk-based and supported by measurable data. A holistic approach to quality risk management (QRM) as it relates to container quality is necessary.

In recent years, regulatory trends have shown increasing preference for deterministic testing technologies. These methods provide quantitative output, improved repeatability, and stronger statistical confidence. Probabilistic methods such as dye ingress face additional scrutiny related to their sensitivity, test result reproducibility and overall scientific validation of the method.

Data integrity is another critical expectation. Electronic records must comply with 21 CFR Part 11 requirements, including secure data storage and audit trails. Manufacturers must show that results are traceable and protected from manipulation.

Ultimately, FDA expectations center on scientific defensibility. A test method must demonstrate that it can reliably detect defects that threaten sterility or stability. Deterministic technologies support QRM strategies and satisfying this requirement by generating objective measurements that align with modern regulatory standards.